Baseline Ellipsoid Zone Integrity Features as Predictors of Geographic Atrophy Growth Rate in the Phase 3 GATHER Clinical Trials

Related

• 

  Association of Metformin Use and New-Onset of ICD-Coding of Geographic Atrophy

  Dimitra Skondra, MD,PhD

  Annual Meeting Talks

  2024

• 

  Twelve Month Safety and Efficacy Outcomes from a Phase 2 Study of APL-2 in Patients with Geographic Atrophy

  David S. Boyer, MD

  Updates from the Field

  2017

• 

  Expert Panel: Pegcetacoplan Safety

  Andre J. Witkin, MD

  David A. Eichenbaum, MD, FASRS

  Samuel Anthony Minaker, MD, MSc

  Janani Singaravelu, MS, MD

  Sunir J. Garg, MD, FACS, FASRS

  Annual Meeting Talks

  2024